Fondazione Telethon announces the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

Samson Clinical (Samson), an Australian pharmaceutical company focused on developing innovative treatments for hair loss, today announced the successful completion of recruitment in its SAM-002 Phase ...

Amid high demand for mental health care, some individuals have turned to AI chatbots for emotional support — but a new study ...

Study researchers noted that the findings suggest the association between anxiety and improved OS was at least partly related to the higher incidence of irAEs, which implies that, in people with an ...

On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology ...

NEW ORLEANS – A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that ...

A new study published in the Journal of the American Heart Association has found that women patients with culture-negative ...

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

Researchers sought to determine whether glofitamab would induce responses in real-world cases of relapsed or refractory DLBCL.

A new research paper documents the outcomes of five volunteers who continued to receive 40Hz light and sound stimulation for ...

Eruptive xanthoma is considered a rare disease with an incidence of 18 out of 100,000. It can only be seen in 10% of patients ...